The overall aim of this project is to establish a transgenic mouse model to examine interactions between human immunodeficiency virus (HIV) and human cytomegalovirus (HCMV) which can contribute to the pathogenesis of Acquired Immune Deficiency Syndrome (AIDS). HCMV is one of the most common and importnat pathogens in patients with AIDS. HCMV possesses many similarities to HIV including suppression of the immune system and infection in vivo of monocyte/macrophages and endothelial cells. The ability of HYCMV to increase expression of HIV in vitro in the context of our recent colocalization of both viruses in single cells in brain tissue from AIDS patients with aberrant HCMV spread strongly suggests these viruses may potentiate each others growth. This application builds on these observations to develop a transgenic mouse model to examine specific interactions between HCMV and HIV in the animal. We have developed several founder lines of transgenic mice containing HCMV immediate-early (IE) genes which transactivate the HIV LTR. These HCMV IE mice will be crossed with several transgenic mouse lines containing different HIV constructs. Progeny from these crosses will be examined for tissue specific expression of HIV genes and HCMV IE genes by northern blot, in situ hybridization and immunocytochemistry. Phenotypic changes associated with expression of these viral genes will be determined by histopathology. We will determine whether HCMV IE mice can reactivate HIV expression in mice containing inactive HIV constructs. Finally, we will cross HCMV IE mice expressing viral transactivatying proteins in the brain with transgenic lines containing either HIV LTR gp160, gp120 or gp41 constructs to determine whehter we can target brain specific expression of HIV glycoproteins. These experiments will address the issue of whether HIV glycoproteins are directly involved in tissue damage in the CNS. Progeny mice will be examined for phenotypic changes associated with HIV glycoprotein expression in the brain. These transgenic mice will provide an important model to dissect disease processes of viruses restricted to human growth.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA050151-03
Application #
3194443
Study Section
Special Emphasis Panel (SRC (56))
Project Start
1989-03-17
Project End
1992-02-29
Budget Start
1991-03-01
Budget End
1992-02-29
Support Year
3
Fiscal Year
1991
Total Cost
Indirect Cost
Name
Scripps Research Institute
Department
Type
DUNS #
City
La Jolla
State
CA
Country
United States
Zip Code
92037
Baskar, J F; Smith, P P; Nilaver, G et al. (1996) The enhancer domain of the human cytomegalovirus major immediate-early promoter determines cell type-specific expression in transgenic mice. J Virol 70:3207-14
Baskar, J F; Smith, P P; Ciment, G S et al. (1996) Developmental analysis of the cytomegalovirus enhancer in transgenic animals. J Virol 70:3215-26
Fish, K N; Stenglein, S G; Ibanez, C et al. (1995) Cytomegalovirus persistence in macrophages and endothelial cells. Scand J Infect Dis Suppl 99:34-40
Fish, K N; Depto, A S; Moses, A V et al. (1995) Growth kinetics of human cytomegalovirus are altered in monocyte-derived macrophages. J Virol 69:3737-43
Jupp, R; Hoffmann, S; Depto, A et al. (1993) Direct interaction of the human cytomegalovirus IE86 protein with the cis repression signal does not preclude TBP from binding to the TATA box. J Virol 67:5595-604
Jupp, R; Hoffmann, S; Stenberg, R M et al. (1993) Human cytomegalovirus IE86 protein interacts with promoter-bound TATA-binding protein via a specific region distinct from the autorepression domain. J Virol 67:7539-46
Baracchini, E; Glezer, E; Fish, K et al. (1992) An isoform variant of the cytomegalovirus immediate-early auto repressor functions as a transcriptional activator. Virology 188:518-29
Ghazal, P; Young, J; Giulietti, E et al. (1991) A discrete cis element in the human immunodeficiency virus long terminal repeat mediates synergistic trans activation by cytomegalovirus immediate-early proteins. J Virol 65:6735-42